Dr. Hilary Gomolin, MD

Dr. Gomolin practices at Boca Raton Regional Hospital in Boca Raton, Florida, part of Baptist Health South Florida.

Dr. Gomolin's NPI, 1104874916, was assigned on May 4, 2006. Dr. Gomolin graduated from McGill University Faculty of Medicine in 1986. Dr. Gomolin holds Florida license 77729.

Dr. Gomolin's primary practice is Boca Raton Regional Hospital, at 800 Meadows Rd, Boca Raton, FL 33486 in Palm Beach County. The practice phone is (561) 955-4200.

Dr. Gomolin's primary practice is Boca Raton Regional Hospital in Boca Raton, Florida, part of Baptist Health South Florida. Dr. Gomolin is also affiliated with Bethesda Hospital East. The medical group on file is Eugene M. & Christine E. Lynn Cancer Institute (Lynn Cancer Institute). Dmand AI also links Dr. Gomolin to 1 more hospital, 2 home health agencies and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gomolin practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Gomolin's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Gomolin is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Gomolin's licenses on file in 2 states: Florida and Massachusetts.

Dmand AI lists arterial blot clot /embolism, breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, deep vein thrombosis (DVT), immune deficiency disease and lung cancer among the conditions Dr. Gomolin treats.

CMS data shows 3,621 Medicare services from Dr. Gomolin across 9 procedure codes in 2024, for 804 Medicare patients. Medicare paid $183,651 for them.

CMS counts 804 Medicare patients who saw Dr. Gomolin in 2024. The largest group is 75 to 84, with 380 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 5% are also on Medicaid. Their average risk score is 2.37, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gomolin's median patient age at 78, with 43% women.

In 2024, Dr. Gomolin wrote 1,044 Medicare Part D claims for 232 patients. 56% of them were for generic drugs. CMS names the drug for 843 of them, across 30 drugs with 11 or more claims each, at $5,903,771 in total drug cost. In 2023, CMS named 712 claims across 27 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Gomolin for performance year 2024, reported individually. Dr. Gomolin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 5 papers to Dr. Gomolin. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell and Head and Neck Neoplasms. Dr. Gomolin's most frequent co-authors are Philip Crawford Amrein, MD, Alexander Dimitrios Colevas, MD and Marshall R. Posner, MD.

Dmand AI links Dr. Gomolin to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Lymphoid Interstitial Pneumonia and Tongue Neoplasms.

CMS Open Payments shows 702 general payments to Dr. Gomolin from 55 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 95% of the total. Celgene Corporation paid the most, $1,240.

Dmand AI lists 1 award for Dr. Gomolin, most recently CMS Stage 1 EHR in 2013.

Dr. Gomolin graduated from McGill University Faculty of Medicine in 1986.

Dr. Gomolin is in network with 12 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.